Skip to main content
Premium Trial:

Request an Annual Quote

IntelligentMDx Nets $3M Investment

NEW YORK (GenomeWeb News) – Cambridge, Mass.-based molecular diagnostics company IntelligentMDx has raised $3 million in a financing from two undisclosed investors, the company said on Tuesday.

The company will use the funds to develop tests for specific viral and bacterial nucleic acid targets using a proprietary bioinformatics approach. It makes molecular diagnostic test kits for transplantation, fungal infection, blood screening, meningitis/encephalitis, and respiratory disease.

The company said it raised the $3 million through a Series D preferred stock offering it began on May 12. IntelligentMDx also noted that it has raised a total of $26.5 million through funding from non-venture capital investors since 2004.